287407-57-2

Upstream product

• 37763-23-8 D-2-p-hydroxyphenylglycine methyl ester 
• 82911-69-1 N-(9H-fluoren-2-ylmethoxycarbonyloxy)succinimide 
• 57591-61-4 methyl (R)-2-amino-2-(4-hydroxyphenyl)acetate hydrochloride 
• 22818-40-2 D-4-hydroxyphenylglycine 
• 28920-43-6 (fluorenylmethoxy)carbonyl chloride 
• 43189-12-4 (R)-methyl 2-amino-2-(4-hydroxyphenyl)acetate 

Downstream Products

• 608518-57-6 (R)-(4-But-2-ynyloxy-benzenesulfonylamino)-[4-(2-methylamino-ethoxy)-phenyl]-acetic acid 

Relevant academic research and scientific papers

Intermediate of RORgamma inhibitor and preparation method thereof

The invention belongs to the technical field of drugs, in particular to an intermediate of a RORgamma inhibitor and a preparation method thereof. The intermediate is as shown in a formula (I). The method has the advantages of being easily available in raw material, concise in process, economic and environment-friendly, high in yield and the like. The formula is as shown in the description.

NOVEL ANTIESTROGENIC HETEROCYCLIC COMPOUNDS

The present invention provides novel heterocyclic compounds of Formula I wherein A, B, E, ring Z, Y, L, ring X, D, m, n, R7 and R8 are as defined in the specification as estrogen receptor antagonists/degraders. The compound of Formula I can be used for the treatment of cancers mediated by estrogen receptors. (Formula I ).

ACETYLENIC ALPHA-AMINO ACID-BASED SULFONAMIDE HYDROXAMIC ACID TACE INHIBITORS

Compound of the formula (B) are useful in treating disease conditions mediated by TNF- alpha , such as rheumatoid arthritis, osteoarthritis, sepsis, AIDS, ulcerative colitis, multiple sclerosis, Crohn's disease and degenerative cartilage loss.

Acetylenic α-amino acid-based sulfonamide hydroxamic acid tace inhibitors

Compounds of the formula: are useful in treating disease conditions mediated by TNF-α, such as rheumatoid arthritis, osteoarthritis, sepsis, AIDS, ulcerative colitis, multiple sclerosis, Crohn's disease and degenerative cartilage loss.